On Friday, Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) increased 0.88% and closed at $34.36 after opening 34.19 with the overall traded volume of 962,283 shares. The company’s Market capitalization reached to $1.90 billion, $54.96 million outstanding shares. Its low price was $33.61 and the highest price was $34.58.
Sarepta Therapeutics Inc (SRPT) on June 28, 2017 announced the appointment of Douglas S. Ingram as president and chief executive officer. He will also serve on the Company’s board of directors. Mr. Ingram brings to Sarepta Therapeutics more than two decades of executive leadership experience in the life sciences.
As previously announced, Edward M. Kaye, M.D., will step down from his positions at the Company, but is expected to serve the Company in an advisory capacity to ensure a smooth transition.
“This is a transformational period in Sarepta Therapeutics’ evolution, and Doug is an exceptional executive with the vision, experience, and leadership skills required to realize the Company’s full potential during its next phase. We look forward to officially introducing Doug during our second quarter earnings conference call,” said M. Kathleen Behrens, Ph.D., chair of Sarepta’s board of directors. “Our team remains steadfast in its goal to ensure patients with Duchenne muscular dystrophy (DMD) and their families have access to the best treatments. We look forward to working with Doug to continue helping those with serious unmet medical needs and thank Ed for his career-long pursuit to improve the lives of these patients, as well as his tremendous leadership to help bring EXONDYS 51® to patients and physicians.”
“I am confident Sarepta has selected in Doug Ingram the right leader to build on our success to date and to drive value for the Company as he has done for Allergan and Chase Pharmaceuticals,” stated Dr. Kaye. “I am proud of our accomplishments over the past several years and more importantly I have enjoyed becoming a member of the Duchenne community. I look forward to supporting the Company and Doug through this transition as we continue to advance our strong pipeline to full fruition.”
Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) increased 1.44% and closed at $2.82 after opening 2.77 with the overall traded volume of 295,937 shares. The company’s Market capitalization reached to $239.68 million, $83.79 million outstanding shares. Its low price was $2.74 and the highest price was $2.83. The EPS is -0.21.
Catalyst Pharmaceuticals Inc (CPRX), a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. Its lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. The company also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and Tourette disorder; and CPP-109 to treat Tourette disorder. It has a strategic collaboration with BioMarin Pharmaceutical Inc. for the development of Firdapse. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.